Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Adv Chronic Kidney Dis. 2022 Mar;29(2):188–200.e1. doi: 10.1053/j.ackd.2021.09.002

Figure 2.

Figure 2.

Complexity of immune checkpoint inhibitor use in patients with kidney transplants. The figure highlights the complexity of immune suppression–associated adverse effects (eg, cancers [left] and infections [middle]) and benefits (eg, achieving allograft tolerance [right]). Abbreviation: PTLD, post-transplant lymphoproliferative disorder.